Compare HPI & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HPI | RCEL |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 360.0M | 403.3M |
| IPO Year | 2002 | 2018 |
| Metric | HPI | RCEL |
|---|---|---|
| Price | $12.71 | $15.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.10 |
| AVG Volume (30 Days) | 116.9K | ★ 540.5K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.20 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $71,610,000.00 |
| Revenue This Year | N/A | $33.44 |
| Revenue Next Year | N/A | $21.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.45 |
| 52 Week Low | $12.83 | $3.22 |
| 52 Week High | $17.07 | $18.43 |
| Indicator | HPI | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 31.64 | 54.17 |
| Support Level | N/A | $14.67 |
| Resistance Level | $16.39 | $16.90 |
| Average True Range (ATR) | 0.23 | 1.23 |
| MACD | -0.00 | -0.13 |
| Stochastic Oscillator | 22.95 | 28.72 |
John Hancock Preferred Income Fund is a closed-end, diversified management investment company. Its primary investment objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary objective. It seeks to achieve its investment objectives by investing in securities that may be undervalued relative to similar securities in the marketplace. The fund's principal investment strategies include investing a majority of its assets in preferred stocks and other preferred securities. Its portfolio composition consists of U.S preferred securities, common stocks, foreign preferred securities, corporate bonds, and short-term investments.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.